Publications 2024

Behsen AD, Holien T, Micci F, Rye M, Rasmussen JM, Andersen K, Hess ES, Børset M, Keats J, Våtsveen TK, Misund K (2024)
Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
Sci Rep, 14 (1), 28805
DOI 10.1038/s41598-024-80263-y, PubMed 39567630

Christensen E, Foss OA, Holien T, Juzenas P, Peng Q (2024)
Application of Photodynamic Therapy with 5-Aminolevulinic Acid to Extracorporeal Photopheresis in the Treatment of Cutaneous T-Cell Lymphoma: A First-in-Human Phase I/II Study
Pharmaceutics, 16 (6)
DOI 10.3390/pharmaceutics16060815, PubMed 38931936

Publications 2023

Andersson-Rusch C, Liu B, Quist-Løkken I, Upton PD, Olsen OE, Hella H, Yang X, Tong Z, Morrell NW, Holien T, Li W (2023)
High concentrations of soluble endoglin can inhibit BMP9 signaling in non-endothelial cells
Sci Rep, 13 (1), 6639
DOI 10.1038/s41598-023-33352-3, PubMed 37095146

Quist-Løkken I, Andersson-Rusch C, Kastnes MH, Kolos JM, Jatzlau J, Hella H, Olsen OE, Sundan A, Knaus P, Hausch F, Holien T (2023)
FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells
Cell Commun Signal, 21 (1), 25
DOI 10.1186/s12964-022-01033-9, PubMed 36717825

Publications 2022

Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS (2022)
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
Front Oncol, 12, 1040730
DOI 10.3389/fonc.2022.1040730, PubMed 36523963

Publications 2021

Christensen E, Foss OA, Quist-Paulsen P, Staur I, Pettersen F, Holien T, Juzenas P, Peng Q (2021)
Application of Photodynamic Therapy with 5-Aminolevulinic Acid to Extracorporeal Photopheresis in the Treatment of Patients with Chronic Graft-versus-Host Disease: A First-in-Human Study
Pharmaceutics, 13 (10)
DOI 10.3390/pharmaceutics13101558, PubMed 34683851

Kolos JM, Pomplun S, Jung S, Rieß B, Purder PL, Voll AM, Merz S, Gnatzy M, Geiger TM, Quist-Løkken I, Jatzlau J, Knaus P, Holien T, Bracher A, Meyners C, Czodrowski P, Krewald V, Hausch F (2021)
Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides
Chem Sci, 12 (44), 14758-14765
DOI 10.1039/d1sc04638a, PubMed 34820091

Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS (2021)
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Mol Oncol, 16 (5), 1153-1170
DOI 10.1002/1878-0261.13153, PubMed 34861096

Publications 2020

Darvekar S, Juzenas P, Oksvold M, Kleinauskas A, Holien T, Christensen E, Stokke T, Sioud M, Peng Q (2020)
Selective Killing of Activated T Cells by 5-Aminolevulinic Acid Mediated Photodynamic Effect: Potential Improvement of Extracorporeal Photopheresis
Cancers (Basel), 12 (2)
DOI 10.3390/cancers12020377, PubMed 32041351

Ianevski A, Kulesskiy E, Krpina K, Lou G, Aman Y, Bugai A, Aasumets K, Akimov Y, Bulanova D, Gildemann K, Arutyunyan AF, Susova OY, Zhuze AL, Ji P, Wang W, Holien T, Bugge M, Zusinaite E, Oksenych V, Lysvand H, Gerhold JM, Bjørås M, Johansen P, Waage A, Heckman CA et al. (2020)
Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061694, PubMed 32630560

Martinez-Hackert E, Sundan A, Holien T (2020)
Receptor binding competition: A paradigm for regulating TGF-β family action
Cytokine Growth Factor Rev, 57, 39-54
DOI 10.1016/j.cytogfr.2020.09.003, PubMed 33087301

Olsen OE, Hella H, Elsaadi S, Jacobi C, Martinez-Hackert E, Holien T (2020)
Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors
Biomolecules, 10 (4)
DOI 10.3390/biom10040519, PubMed 32235336

Publications 2019

Neckmann U, Wolowczyk C, Hall M, Almaas E, Ren J, Zhao S, Johannessen B, Skotheim RI, Bjørkøy G, Ten Dijke P, Holien T (2019)
GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients
Cell Commun Signal, 17 (1), 140
DOI 10.1186/s12964-019-0467-7, PubMed 31694641

Westhrin M, Holien T, Zahoor M, Moen SH, Buene G, Størdal B, Hella H, Yuan H, de Bruijn JD, Martens A, Groen RW, Bosch F, Smith U, Sponaas AM, Sundan A, Standal T (2019)
Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone
JBMR Plus, 4 (1), e10247
DOI 10.1002/jbm4.10247, PubMed 31956851

Publications 2018

Holien T, Gederaas OA, Darvekar SR, Christensen E, Peng Q (2018)
Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo
Lasers Surg Med, 50 (5), 469-475
DOI 10.1002/lsm.22806, PubMed 29460964

Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A (2018)
Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
Oncotarget, 9 (89), 36048
DOI 10.18632/oncotarget.26373, PubMed 30542518

Olsen OE, Sankar M, Elsaadi S, Hella H, Buene G, Darvekar SR, Misund K, Katagiri T, Knaus P, Holien T (2018)
BMPR2 inhibits activin and BMP signaling via wild-type ALK2
J Cell Sci, 131 (11)
DOI 10.1242/jcs.213512, PubMed 29739878

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

Olsen OE, Skjærvik A, Størdal BF, Sundan A, Holien T (2017)
TGF-β contamination of purified recombinant GDF15
PLoS One, 12 (11), e0187349
DOI 10.1371/journal.pone.0187349, PubMed 29161287

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017)
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Haematologica, 102 (7), 1266-1272
DOI 10.3324/haematol.2016.160564, PubMed 28385781

Tangen JM, Holien T, Mirlashari MR, Misund K, Hetland G (2017)
Cytotoxic Effect on Human Myeloma Cells and Leukemic Cells by the Agaricus blazei Murill Based Mushroom Extract, Andosan™
Biomed Res Int, 2017, 2059825
DOI 10.1155/2017/2059825, PubMed 29238712

Publications 2016

Abdollahi P, Vandsemb EN, Hjort MA, Misund K, Holien T, Sponaas AM, Rø TB, Slørdahl TS, Børset M (2016)
Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3
Mol Cancer Res, 15 (1), 69-77
DOI 10.1158/1541-7786.MCR-16-0212, PubMed 27698077

Baranowska K, Misund K, Starheim KK, Holien T, Johansson I, Darvekar S, Buene G, Waage A, Bjørkøy G, Sundan A (2016)
Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
Oncotarget, 7 (43), 70845-70856
DOI 10.18632/oncotarget.12226, PubMed 27683126

Starheim KK, Holien T, Misund K, Johansson I, Baranowska KA, Sponaas AM, Hella H, Buene G, Waage A, Sundan A, Bjørkøy G (2016)
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
Blood Cancer J, 6 (7), e446
DOI 10.1038/bcj.2016.56, PubMed 27421095

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
Genes Chromosomes Cancer, 55 (11), 890-901
DOI 10.1002/gcc.22388, PubMed 27311012

Publications 2015

Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A (2015)
MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
Oncotarget, 6 (26), 22698-705
DOI 10.18632/oncotarget.4245, PubMed 26087190

Jung KY, Wang H, Teriete P, Yap JL, Chen L, Lanning ME, Hu A, Lambert LJ, Holien T, Sundan A, Cosford ND, Prochownik EV, Fletcher S (2015)
Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics
J Med Chem, 58 (7), 3002-24
DOI 10.1021/jm501440q, PubMed 25734936

Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, Waage A, Sundan A, Holien T (2015)
Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B
Cell Commun Signal, 13, 27
DOI 10.1186/s12964-015-0104-z, PubMed 26047946

Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, Grøseth LA, Størdal B, Buene G, Espevik T, Waage A, Standal T, Sundan A (2015)
The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma
Immun Inflamm Dis, 3 (2), 94-102
DOI 10.1002/iid3.53, PubMed 26029369

Wang H, Teriete P, Hu A, Raveendra-Panickar D, Pendelton K, Lazo JS, Eiseman J, Holien T, Misund K, Oliynyk G, Arsenian-Henriksson M, Cosford ND, Sundan A, Prochownik EV (2015)
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids
Oncotarget, 6 (32), 32380-95
DOI 10.18632/oncotarget.6116, PubMed 26474287

Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T (2015)
Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease
Haematologica, 100 (12), e511-4
DOI 10.3324/haematol.2015.124511, PubMed 26294726

Publications 2014

Holien T, Sundan A (2014)
The role of bone morphogenetic proteins in myeloma cell survival
Cytokine Growth Factor Rev, 25 (3), 343-50
DOI 10.1016/j.cytogfr.2014.04.009, PubMed 24853340

Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T (2014)
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin
Blood Cancer J, 4 (3), e196
DOI 10.1038/bcj.2014.16, PubMed 24658374

Publications 2013

Holien T, Olsen OE, Misund K, Hella H, Waage A, Rø TB, Sundan A (2013)
Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate
Eur J Haematol, 91 (4), 339-46
DOI 10.1111/ejh.12176, PubMed 23869695

Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Børset M, Waage A, Sundan A (2013)
A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells
J Biomol Screen, 18 (6), 637-46
DOI 10.1177/1087057113478168, PubMed 23446700

Müller R, Misund K, Holien T, Bachke S, Gilljam KM, Våtsveen TK, Rø TB, Bellacchio E, Sundan A, Otterlei M (2013)
Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells
PLoS One, 8 (7), e70430
DOI 10.1371/journal.pone.0070430, PubMed 23936203

Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Børset M (2013)
HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase
Exp Hematol, 41 (7), 646-55
DOI 10.1016/j.exphem.2013.03.002, PubMed 23499762

Publications 2012

Holien T, Sundan A (2012)
Oncogene addiction to c-MYC in myeloma cells
Oncotarget, 3 (8), 739-40
DOI 10.18632/oncotarget.631, PubMed 22964579

Holien T, Våtsveen TK, Hella H, Waage A, Sundan A (2012)
Addiction to c-MYC in multiple myeloma
Blood, 120 (12), 2450-3
DOI 10.1182/blood-2011-08-371567, PubMed 22806891

Publications 2011

Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, Janz M (2011)
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells
Oncogene, 30 (28), 3198-206
DOI 10.1038/onc.2011.79, PubMed 21478911

Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A, Sundan A (2011)
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC
Leukemia, 26 (5), 1073-80
DOI 10.1038/leu.2011.263, PubMed 21941367

Publications 2010

Nørgaard NN, Holien T, Jönsson S, Hella H, Espevik T, Sundan A, Standal T (2010)
CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis
J Immunol, 185 (6), 3131-9
DOI 10.4049/jimmunol.0903605, PubMed 20702733

Publications 2009

Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A (2009)
c-Met signaling promotes IL-6-induced myeloma cell proliferation
Eur J Haematol, 82 (4), 277-87
DOI 10.1111/j.1600-0609.2009.01212.x, PubMed 19187270

Publications 2007

Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD, Sundan A, Børset M (2007)
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Blood, 111 (2), 806-15
DOI 10.1182/blood-2007-07-101139, PubMed 17934070

Publications 2000

Munthe E, Rian E, Holien T, Rasmussen A, Levy FO, Aasheim H (2000)
Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6
FEBS Lett, 466 (1), 169-74
DOI 10.1016/s0014-5793(99)01793-7, PubMed 10648835